Characterization of Esophageal Microbiota in Patients With Esophagitis and Esophageal Squamous Cell Carcinoma
Overview
Infectious Diseases
Microbiology
Affiliations
Microbial imbalances have been well elucidated in esophageal adenocarcinoma. However, few studies address the microbiota in esophageal squamous cell carcinoma (ESCC) and esophagitis (ES). We aimed to explore the association of esophageal microbiota with these patients. Esophageal tissues were obtained from healthy controls and ES and ESCC patients undergoing upper endoscopy. 16S rRNA gene sequencing was applied to analyze the microbiome. The α and β diversity differences were tested by Tukey test and partial least squares-discriminant analysis (PLS-DA), respectively. Linear discriminant analysis effect size (LEfSe) analysis was performed to assess taxonomic differences between groups. A total of 68 individuals were enrolled (control = 21, ES = 15, ESCC = 32). Microbial diversity was significantly different between the ESCC patients and healthy controls by Chao1 index, Shannon index, and PLS-DA. , , , , and were the five dominant bacterial phyla among the three groups. , , , and showed a significantly continuous decreasing trend from the control group to the ESCC group at the genus level. When compared with the control group, decreased at phylum level and , , , and at genus level were detected. ESCC samples also displayed a striking reduction of , , , and in comparison with the ES patients. LEfSe analysis indicated a greater abundance of , , , , and in the ESCC group. Our study suggests a potential association between esophageal microbiome dysbiosis and ESCC and provides insights into potential screening markers for esophageal cancer.
Microbiota and Radiotherapy: Unlocking the Potential for Improved Gastrointestinal Cancer Treatment.
Vucinic D, Redzovic A, Hauser G, Mikolasevic I Biomedicines. 2025; 13(2).
PMID: 40002939 PMC: 11852588. DOI: 10.3390/biomedicines13020526.
Mechanistic Insights on Microbiota-Mediated Development and Progression of Esophageal Cancer.
Moe K, Tan K Cancers (Basel). 2024; 16(19).
PMID: 39409925 PMC: 11475040. DOI: 10.3390/cancers16193305.
Shi H, Tan Y, Ma C, Wei Y, Shi F, Wang J Front Oncol. 2024; 14:1397960.
PMID: 39314629 PMC: 11416913. DOI: 10.3389/fonc.2024.1397960.
Mechanism of action of FoxiangSan in diabetic gastroparesis: Gut microbiota and cAMP/PKA pathway.
Huang J, Song Y, Cheng S, Yang X Heliyon. 2024; 10(16):e35558.
PMID: 39211931 PMC: 11357790. DOI: 10.1016/j.heliyon.2024.e35558.
Ni Y, Tong Q, Xu M, Gu J, Ye H Mol Neurobiol. 2024; 62(2):2480-2492.
PMID: 39134825 DOI: 10.1007/s12035-024-04370-7.